.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Predict branded drug patent expiration
  • Identify first generic entrants

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Fish and Richardson
Federal Trade Commission
McKesson
Boehringer Ingelheim
Chinese Patent Office
US Army
Argus Health
Deloitte
Johnson and Johnson

Generated: July 20, 2017

DrugPatentWatch Database Preview

BIAXIN Drug Profile

« Back to Dashboard

What is the patent landscape for Biaxin, and when can generic versions of Biaxin launch?

Biaxin is a drug marketed by Abbvie and is included in three NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in BIAXIN is clarithromycin. There are twenty-one drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the clarithromycin profile page.

Summary for Tradename: BIAXIN

Patents:0
Applicants:1
NDAs:3
Suppliers / Packagers: see list7
Bulk Api Vendors: see list35
Clinical Trials: see list34
Patent Applications: see list5,302
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:BIAXIN at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie
BIAXIN
clarithromycin
TABLET;ORAL050662-001Oct 31, 1991ABRXYesYes► Subscribe► Subscribe
Abbvie
BIAXIN XL
clarithromycin
TABLET, EXTENDED RELEASE;ORAL050775-001Mar 3, 2000DISCNYesNo6,010,718► SubscribeY ► Subscribe
Abbvie
BIAXIN
clarithromycin
FOR SUSPENSION;ORAL050698-003Sep 30, 1998DISCNNoNo► Subscribe► Subscribe
Abbvie
BIAXIN
clarithromycin
TABLET;ORAL050662-002Oct 31, 1991ABRXYesYes► Subscribe► Subscribe
Abbvie
BIAXIN
clarithromycin
FOR SUSPENSION;ORAL050698-001Dec 23, 1993ABRXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: BIAXIN

Drugname Dosage Strength RLD Submissiondate
clarithromycinExtended-release Tablet500 mgBiaxin XL12/6/2010
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Cantor Fitzgerald
Fuji
Federal Trade Commission
Chinese Patent Office
Citi
QuintilesIMS
Colorcon
Healthtrust
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot